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Background
MHC II presentation of antigenic peptides to CD4 T cell is
critical for the initiation of the primary immune response
as well as for the maintenance of the secondary immune
response. Previously we have shown that gp120-specific
human CD4+ T cell responses are inhibited in the pres-
ence of antibodies to the CD4-binding site of gp120
(CD4bs) [1,2]. But the role of these antibodies in modu-
lating the immune responses to gp120 in vivo is not yet
determined.
Materials and methods
The current study used the murine system to address the
effects of anti-CD4bs antibodies on the presentation of
gp120 antigen to MHC class II-restricted CD4 T cell and B
cells. First, gp120 uptake and processing were assessed
using mouse spleen cells as APCs in the presence of
CD4bs or irrelevant mAbs. A sandwich ELISA was used to
detect the remaining intact gp120 associated with the
APCs over time. Gp120 presentation was then assessed
with or without CD4bs mAbs using a gp120-specific
mouse CD4 T cell clone in a T-cell proliferation assay.
Structural changes induced by the CD4bs mAb binding
that result in increased exposure of specific Ab epitopes
were also assessed by ELISA. Finally, the in vivo effects of
anti CD4bs mAbs were evaluated in Balb/c mice that had
been immunized with gp120 complexed with CD4bs or
control mAbs. Both lymphoproliferation and Ab
responses were examined.
Results
Upon binding to gp120, CD4bs mAbs inhibited gp120
antigen processing in mouse APCs, such that gp120 com-
plexed with anti-CD4bs antibody was mostly intact after
8 days in culture. In contrast, gp120 mixed with an irrele-
vant antibody was totally digested by the cells. Consistent
with these results, the CD4bs Abs significantly suppressed
the presentation of gp120 to mouse CD4 T cells. Further-
more, the binding of CD4bs mAb also induced structural
alterations that increased the exposure of Ab epitopes in
C1 and V3 but not in C5 and C2. When mice were immu-
nized with gp120 in the presence of CD4bs mAbs, weaker
lymphoproliferation (SI = 8) in response to gp120 was
detected as compared to mice immunized with gp120
mixed with other mAbs (SI = 14). However, the mice
immunized with the gp120/CD4bs complex had a higher
titer of antibodies specific for gp120 and particularly Abs
directed to V3.
Conclusion
Anti-CD4bs mAbs suppress gp120 antigen presentation to
CD4 T cells both in vitro and in vivo due to their capacity
to block gp120 processing. However, the binding of these
Abs to gp120 increased the antigenic exposure of specific
regions of gp120, resulting in induction of higher titers of
Abs to gp120. Further studies are needed to evaluate the
mechanisms by which the CD4bs Abs differentially mod-
ulate CD4 T cell response and antibody response to
gp120.
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